SYDNEY -- Novotech a globally recognized full-service clinical research organization (CRO) and scientific advisory company, announced it has been awarded the Citeline CRO Partnership of the Year Award in recognition of its collaboration with Tune Therapeutics, a pioneering epigenetic editing company. This honor celebrates the teams’ partnership and sets a benchmark for CRO-biotech partnerships.

The CRO Partnership of the Year award honors outstanding collaboration between a CRO and a pharmaceutical or biotech company that has advanced clinical programs through strong alignment and shared goals.

Sarah Anderson, Director of Therapeutic Strategy, and Steve Roan, Associate Director of Business Development, accepted the award on behalf of Novotech at the Citeline Awards ceremony held on May 8, 2025, in Boston. Katie Tarashuck, Vice President of Finance at Tune Therapeutics, attended as a partner representative.

Novotech and Tune Therapeutics’ partnership focuses on a groundbreaking clinical trial program advancing an epigenetic therapy with the potential to revolutionize the treatment landscape for Chronic Hepatitis B (CHB). The partnership combines Novotech’s regulatory, operational, and therapeutic expertise with Tune’s innovative scientific platform and agile development strategy.

“This recognition from Citeline reflects not only the strength of our partnership with Tune Therapeutics but also the dedication of our global teams to help bring novel therapies to patients faster,” said Dr. John Moller, CEO of Novotech. “We are honored to collaborate with visionary biotech companies like Tune and look forward to continuing to deliver clinical excellence across the development spectrum.”

“Tune is delighted to receive this partnership award with Novotech,” said Dr. Heidi Zhang, Chief Development Officer at Tune Therapeutics. “Together, we have achieved a global first in bringing this epigenome editing therapy to the clinic, and new hope to over 250 million people living with CHB worldwide.”

The award acknowledges Novotech’s ability to align closely with biotech partners, applying its regulatory and therapeutic expertise to support the effective delivery of clinical trials across varied global settings.

“The strength of this collaboration,” added Dr. Zhang, “lies in our shared commitment to transparency, willingness to confront challenges directly, and ability to act quickly and effectively as one team.”